Reliant AI

Reliant AI, founded in 2024 by former DeepMind, Google Brain, and EY Parthenon researchers Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel, emerged from stealth with $11.3 million in seed funding co-led by Inovia Capital and Tola Capital.

Reviewed by 7wData
Share Email

On this page

Profile

Reliant AI provides generative AI-powered data analytics software to automate and accelerate decision-making in data-intensive industries like biopharma.

Reliant AI, founded in 2024 by former DeepMind, Google Brain, and EY Parthenon researchers Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel, emerged from stealth with $11.3 million in seed funding co-led by Inovia Capital and Tola Capital. The company focuses on generative AI-powered data analytics, initially targeting the biopharma industry with its flagship product, Reliant Tabular. This AI workbench automates systematic literature reviews, asset scans, and data analysis, achieving 99.9% recall and 92% precision in a case study analyzing 3,000 oncology abstracts.

Reliant AI's proprietary ML models are optimized for biopharma topics, offering a customizable data platform that reduces manual labor and accelerates decision-making. The company is expanding its engineering team and footprint in Europe and North America, capitalizing on the growing demand for AI-driven solutions in life sciences. Its technology addresses critical pain points in data-intensive industries, where professionals often spend excessive time on data wrangling rather than analysis. Reliant AI's approach combines domain expertise with cutting-edge AI research, positioning it as a disruptor in evidence-based research workflows.

Track Reliant AI and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Biopharma companies
  • Life sciences researchers
  • Healthcare analytics teams
  • Enterprise AI adopters in regulated industries
  • Commercial strategy teams in pharmaceuticals

Strengths and what to watch

Strengths

  • Proprietary ML models optimized for biopharma topics, achieving 99.9% recall in literature reviews
  • Team with deep AI research pedigree from DeepMind, Google Brain, and Meta
  • First-mover advantage in applying generative AI to systematic literature reviews in life sciences

Watch for

  • Narrow focus on biopharma may limit near-term market expansion opportunities
  • Competition from general-purpose AI tools adapting to life sciences use cases
  • Dependence on seed funding with no later-stage funding announced yet

Key Information

Founded
2024

Frequently Asked Questions

What does Reliant AI do?

Reliant AI develops generative AI-powered analytics software for data-intensive industries, initially focusing on biopharma. Its flagship product, Reliant Tabular, automates systematic literature reviews and data analysis, helping researchers reduce manual work and accelerate decision-making with domain-specific AI models.

How accurate is Reliant AI's technology?

In a case study analyzing 3,000 oncology abstracts, Reliant AI achieved 99.9% recall and 92% precision. These metrics demonstrate strong performance in identifying relevant research and minimizing false positives for biopharma applications.

Who founded Reliant AI?

Reliant AI was founded in 2024 by Karl Moritz Hermann, Marc Bellemare, and Richard Schlegel, former researchers from DeepMind, Google Brain, and EY Parthenon. The team combines deep AI expertise with industry knowledge.

What industries use Reliant AI's software?

Reliant AI primarily serves biopharma companies, life sciences researchers, and healthcare analytics teams. Its technology addresses data-intensive workflows in regulated industries where professionals spend significant time on data preparation rather than analysis.

How is Reliant AI funded?

The company emerged from stealth with $11.3 million in seed funding co-led by Inovia Capital and Tola Capital. This backing supports its engineering expansion in Europe and North America.

What makes Reliant Tabular different from other AI tools?

Reliant Tabular specializes in biopharma data with proprietary ML models optimized for literature reviews and asset scans. Unlike general-purpose AI, it offers domain-specific customization, addressing pain points unique to life sciences research workflows.

Sources

  1. www.prnewswire.com — Company launch details and seed funding amount
  2. www.reliant.ai — Case study results and product capabilities
  3. www.reliant.ai — Product offering and company positioning
  4. cdn.prod.website-files.com — Technical performance metrics for Reliant Tabular